Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

A Comparison of Sequential Glaucoma Drainage Device Implantation Versus Cyclophotocoagulation Following Failure of a Primary Drainage Device

Levinson, Joshua D. MD; Giangiacomo, Annette L. MD; Beck, Allen D. MD; Pruett, Paul B. MD; Superak, Hillary M. MSPH; Lynn, Michael J. MS; Costarides, Anastasios P. MD, PhD

doi: 10.1097/IJG.0000000000000370
Original Studies

Purpose: To compare sequential glaucoma drainage device (GDD) implantation with transscleral diode cyclophotocoagulation (CPC) following failure of a primary GDD.

Materials and Methods: A retrospective review of all patients who underwent GDD implantation at a single institution over 10 years. Patients who required an additional GDD and/or CPC were analyzed. Success was defined as absence of loss of light perception, reoperation for glaucoma, and intraocular pressure (IOP) >21 or <6 at 2 consecutive visits after an initial 3-month period.

Results: Thirty-two patients received sequential GDD. Twenty-one underwent CPC. Cohorts were statistically similar in regards to age, sex, race, and number of previous surgeries. Preoperatively, the GDD cohort had a lower IOP and better visual acuity. The mean length of follow-up was 37.9 months for the GDD group and 46.3 months for CPC. Both procedures significantly reduced IOP; however, CPC led to a greater reduction (P=0.0172). Survival analysis found the 5-year probability of surgical success to be 65.3% for sequential GDD and 58.0% for CPC (P=0.8678). No cases of phthisis occurred in either group. There were 2 cases of endophthalmitis (6.3%) in the GDD group, and none in the CPC group. In eyes without preexisting corneal edema, estimated corneal decompensation probability at 3 years was 31.6% for GDD and 6.7% for CPC (P=0.0828).

Conclusions: Sequential GDD and CPC are both effective at reducing IOP following the failure of a primary GDD. CPC after GDD failure warrants further investigation as it led to a greater reduction in IOP with fewer serious adverse events.

Departments of *Ophthalmology

Biostatistics and Bioinformatics, Emory University, Atlanta, GA

Supported by NIH Departmental Core Grant EY006360 and Research to Prevent Blindness Inc., New York, NY.

Disclosure: The authors declare no conflict of interest.

Reprints: Anastasios P. Costarides, MD, PhD, Emory Eye Center, 1365-B Clifton Rd, Suite 6152B, Atlanta, GA 30322 (e-mail:

Received March 19, 2015

Accepted December 14, 2015

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.